Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study.

Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with mutation-positive (m+) non-small-cell lung cancer (NSCLC) following chemotherapy.

Patients & Methods: In this open-label, single-arm Phase IV study, patients with m+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response.

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.

Objective: To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand.

Methods: A Markov model comprising 3 health states (progression-free survival, progression, death) was used to estimate the long-term costs and health outcomes under a societal perspective with a lifetime horizon. Intervention was the combination of pemetrexed and cisplatin, AND the comparators were gemcitabine plus cisplatin and carboplatin plus paclitaxel.

Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.

There have been many important advances in personalized therapy for patients with lung cancer, particularly for those with advanced disease. Molecular testing is crucial for implementation of personalized therapy. Although the United States and many Western countries have come far in the implementation of personalized therapy for lung cancer, there are substantial challenges for low- and middle-income countries (LMICs).